(2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid;hydron

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 蝶啶及其衍生物
• 英文名称: (2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid;hydron
• 化学式: C20H23N8O5+
• 分子量: 455.4
• InChiKey: FBOZXECLQNJBKD-ZDUSSCGKSA-O

计算性质

• 辛醇/水分配系数(LogP)：
  -1.7
• 重原子数：
  33
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  212
• 氢给体数：
  6
• 氢受体数：
  11

文献信息

• CONTROLLED RELEASE FORMULATIONS
  申请人：Maggio Edward T.

  公开号：US20090110735A1

  公开（公告）日：2009-04-30

  The present invention provides stable, self-assembling, biocompatible and biodegradable hydrogel formulations, into which one or more compounds may be incorporated allowing for delayed release or controlled release of the incorporated compounds as the hydrogel is degraded in the body.
• Controlled Release Formulations
  申请人：Aegis Therapeutics, LLC

  公开号：US20130089595A1

  公开（公告）日：2013-04-11

  The present invention provides stable, self-assembling, biocompatible and biodegradable hydrogel formulations, into which one or more compounds may be incorporated allowing for delayed release or controlled release of the incorporated compounds as the hydrogel is degraded in the body.
• US8329220B2
  申请人：——

  公开号：US8329220B2

  公开（公告）日：2012-12-11
• US8470370B2
  申请人：——

  公开号：US8470370B2

  公开（公告）日：2013-06-25
• [EN] CONTROLLED RELEASE FORMULATIONS<br/>[FR] FORMULATIONS À LIBÉRATION CONTRÔLÉE
  申请人：AEGIS THERAPEUTICS LLC

  公开号：WO2009029543A1

  公开（公告）日：2009-03-05

  The present invention provides stable, self-assembling, biocompatible and biodegradable hydrogel formulations, into which one or more compounds may be incorporated allowing for delayed release or controlled release of the incorporated compounds as the hydrogel is degraded in the body.